Literature DB >> 25156647

Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.

William B Lea1, Katie N Tapp2, Mark Tann1, Gary D Hutchins1, James W Fletcher1, Matthew S Johnson3.   

Abstract

PURPOSE: To characterize the distribution of absorbed radiation dose after glass microsphere radioembolization for hepatocellular carcinoma (HCC) using yttrium-90 ((90)Y) positron emission tomography/computed tomography (PET/CT).
MATERIALS AND METHODS: In this retrospective study, 64 (90)Y PET/CT scans performed after treatment were evaluated following (90)Y glass-bead radioembolization in patients with advanced HCC. The intended dose to the target volume ranged from 83-129 Gy. Three-dimensional "dose maps" were created from reconstructed PET images using a voxel-based S-value transformation. Liver parenchyma and liver tumors were contoured on cross-sectional imaging and aligned with the created dose maps.
RESULTS: There were 113 tumors examined as part of 64 lobar treatments. The average tumor size was 4.8 cm ± 4.0 with an average tumor dose of 173 Gy ± 109. The average dose to the nontumor parenchyma within the target volume was 93.4 Gy ± 32.6, with on average 50% of the parenchymal voxels receiving > 79 Gy ± 23 and 10% receiving > 173 Gy ± 55. The average and median tumor-to-parenchymal weighted dose ratios were 2.2 and 1.9, respectively.
CONCLUSIONS: Using recommended dosimetry and administration techniques for lobar glass microsphere radioembolization, high doses to target tumors as well as background parenchyma were achieved on average with modest preferential uptake within tumors. There was wide variation in measured tumor and parenchymal doses after hepatic radioembolization for HCC, suggesting the need for continued development of patient-specific dosimetry.
Copyright © 2014 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25156647     DOI: 10.1016/j.jvir.2014.06.028

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  10 in total

1.  Radioembolization with 90Y glass microspheres for hepatocellular carcinoma: significance of pretreatment 11C-acetate and 18F-FDG PET/CT and posttreatment 90Y PET/CT in individualized dose prescription.

Authors:  Chi Lai Ho; Sirong Chen; Shing Kee Cheung; Yim Lung Leung; Kam Chau Cheng; Ka Nin Wong; Yuet Hung Wong; Thomas Wai Tong Leung
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-11       Impact factor: 9.236

2.  Administered activity and outcomes of glass versus resin (90)Y microsphere radioembolization in patients with colorectal liver metastases.

Authors:  Shyam M Srinivas; Elie C Nasr; Vamsi K Kunam; Jennifer A Bullen; Andrei S Purysko
Journal:  J Gastrointest Oncol       Date:  2016-08

Review 3.  Yttrium-90 Radioembolization of Hepatocellular Carcinoma-Performance, Technical Advances, and Future Concepts.

Authors:  Christopher Molvar; Robert Lewandowski
Journal:  Semin Intervent Radiol       Date:  2015-12       Impact factor: 1.513

4.  A review of 3D image-based dosimetry, technical considerations and emerging perspectives in 90Y microsphere therapy.

Authors:  Jim O' Doherty
Journal:  J Diagn Imaging Ther       Date:  2015-04-28

5.  Correlation and Agreement of Yttrium-90 Positron Emission Tomography/Computed Tomography with Ex Vivo Radioembolization Microsphere Deposition in the Rabbit VX2 Liver Tumor Model.

Authors:  Andrew C Gordon; Vanessa L Gates; Sarah B White; Kathleen R Harris; Daniel Procissi; Zhuoli Zhang; Weiguo Li; Donald Samaan; Jodi R Nicolai; Samdeep K Mouli; Kent T Sato; Robert K Ryu; Reed A Omary; Riad Salem; Robert J Lewandowski; Andrew C Larson
Journal:  J Vasc Interv Radiol       Date:  2020-11-12       Impact factor: 3.464

6.  PET/MRI of Hepatic 90Y Microsphere Deposition Determines Individual Tumor Response.

Authors:  Kathryn J Fowler; Nichole M Maughan; Richard Laforest; Nael E Saad; Akash Sharma; Jeffrey Olsen; Christina K Speirs; Parag J Parikh
Journal:  Cardiovasc Intervent Radiol       Date:  2015-12-31       Impact factor: 2.740

7.  Verification Study of Residual Activity Measurements After Yttrium-90 Radioembolization with Glass Microspheres.

Authors:  S C Ebbers; B Kunnen; B J van Nierop; J L M Bemelmans; G C Krijger; M G E H Lam; A J A T Braat
Journal:  Cardiovasc Intervent Radiol       Date:  2020-05-20       Impact factor: 2.740

8.  Yttrium-90 TOF-PET-Based EUD Predicts Response Post Liver Radioembolizations Using Recommended Manufacturer FDG Reconstruction Parameters.

Authors:  Michel Hesse; Philipe d'Abadie; Renaud Lhommel; Francois Jamar; Stephan Walrand
Journal:  Front Oncol       Date:  2021-10-05       Impact factor: 6.244

9.  Post-treatment three-dimensional voxel-based dosimetry after Yttrium-90 resin microsphere radioembolization in HCC.

Authors:  Emile B Veenstra; Simeon J S Ruiter; Robbert J de Haas; Reinoud P H Bokkers; Koert P de Jong; Walter Noordzij
Journal:  EJNMMI Res       Date:  2022-02-04       Impact factor: 3.138

10.  Effects of Respiratory Motion on Y-90 PET Dosimetry for SIRT.

Authors:  Matthew D Walker; Jonathan I Gear; Allison J Craig; Daniel R McGowan
Journal:  Diagnostics (Basel)       Date:  2022-01-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.